Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer

Mohamad Adham Salkeni,1 Wajeeha Rizvi,2 Kyaw Hein,3 Gerald M Higa4 1Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; 2Department of Internal Medicine, West Virginia University, Morgantown, WV, USA; 3Department of Business, Lamar...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Salkeni MA, Rizvi W, Hein K, Higa GM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	ado-trastuzumab emtansine erbb fam-trastuzumab deruxtecan her2 lapatinib margetuximab neratinib neu pertuzumab phesgo trastuzumab tucatinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/46bae7ee4c0f4a189823d454f63a5b4d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:46bae7ee4c0f4a189823d454f63a5b4d
record_format	dspace
spelling	oai:doaj.org-article:46bae7ee4c0f4a189823d454f63a5b4d2021-12-02T17:40:32ZNeu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer1179-1314https://doaj.org/article/46bae7ee4c0f4a189823d454f63a5b4d2021-09-01T00:00:00Zhttps://www.dovepress.com/neu-perspectives-therapies-and-challenges-for-metastatic-her2-positive-peer-reviewed-fulltext-article-BCTThttps://doaj.org/toc/1179-1314Mohamad Adham Salkeni,1 Wajeeha Rizvi,2 Kyaw Hein,3 Gerald M Higa4 1Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; 2Department of Internal Medicine, West Virginia University, Morgantown, WV, USA; 3Department of Business, Lamar University, Houston, TX, USA; 4Departments of Clinical Pharmacy and Medicine, West Virginia University, Morgantown, WV, USACorrespondence: Gerald M HigaDepartments of Clinical Pharmacy and Medicine, West Virginia University, Morgantown, WV, 26506, USAEmail ghiga@hsc.wvu.eduAbstract: Even though gene amplification or protein overexpression occurs in approximately one-fifth of all breast cancers, the discovery of HER2 has, nevertheless, had profound implications for the disease. Indeed, the characterization of the receptor resulted in a number of significant advances. Structurally, unique features provided avenues for the development of numerous compounds with target-specificity; molecularly, biological constructs revealed a highly complex, internal signal transduction pathway with regulatory effects on tumor proliferation, survival, and perhaps, even resistance; and clinically, disease outcomes manifested its predictive and prognostic value. Yet despite the receptor’s utility, the beneficial effects are diminished by tumor recurrence after neo- or adjuvant therapy as well as losses resulting from the inability to cure patients with metastatic disease. What these observations suggest is that while tumor response may be partially linked to uncoupling cell surface message reception and nuclear gene expression, as well as recruitment of the innate immune system, disease progression and/or resistance may involve a reprogrammable signaling mainframe that elicits alternative growth and survival signals. This review attempts to meld current perceptions related to HER2-positive metastatic breast cancer with particular attention to current biological insights and therapeutic challenges.Keywords: ado-trastuzumab emtansine, ErbB, Fam-trastuzumab deruxtecan, HER2, lapatinib, margetuximab, neratinib, neu, pertuzumab, PHESGO, trastuzumab, tucatinibSalkeni MARizvi WHein KHiga GMDove Medical Pressarticleado-trastuzumab emtansineerbbfam-trastuzumab deruxtecanher2lapatinibmargetuximabneratinibneupertuzumabphesgotrastuzumabtucatinibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 13, Pp 539-557 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ado-trastuzumab emtansine erbb fam-trastuzumab deruxtecan her2 lapatinib margetuximab neratinib neu pertuzumab phesgo trastuzumab tucatinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	ado-trastuzumab emtansine erbb fam-trastuzumab deruxtecan her2 lapatinib margetuximab neratinib neu pertuzumab phesgo trastuzumab tucatinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Salkeni MA Rizvi W Hein K Higa GM Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
description	Mohamad Adham Salkeni,1 Wajeeha Rizvi,2 Kyaw Hein,3 Gerald M Higa4 1Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; 2Department of Internal Medicine, West Virginia University, Morgantown, WV, USA; 3Department of Business, Lamar University, Houston, TX, USA; 4Departments of Clinical Pharmacy and Medicine, West Virginia University, Morgantown, WV, USACorrespondence: Gerald M HigaDepartments of Clinical Pharmacy and Medicine, West Virginia University, Morgantown, WV, 26506, USAEmail ghiga@hsc.wvu.eduAbstract: Even though gene amplification or protein overexpression occurs in approximately one-fifth of all breast cancers, the discovery of HER2 has, nevertheless, had profound implications for the disease. Indeed, the characterization of the receptor resulted in a number of significant advances. Structurally, unique features provided avenues for the development of numerous compounds with target-specificity; molecularly, biological constructs revealed a highly complex, internal signal transduction pathway with regulatory effects on tumor proliferation, survival, and perhaps, even resistance; and clinically, disease outcomes manifested its predictive and prognostic value. Yet despite the receptor’s utility, the beneficial effects are diminished by tumor recurrence after neo- or adjuvant therapy as well as losses resulting from the inability to cure patients with metastatic disease. What these observations suggest is that while tumor response may be partially linked to uncoupling cell surface message reception and nuclear gene expression, as well as recruitment of the innate immune system, disease progression and/or resistance may involve a reprogrammable signaling mainframe that elicits alternative growth and survival signals. This review attempts to meld current perceptions related to HER2-positive metastatic breast cancer with particular attention to current biological insights and therapeutic challenges.Keywords: ado-trastuzumab emtansine, ErbB, Fam-trastuzumab deruxtecan, HER2, lapatinib, margetuximab, neratinib, neu, pertuzumab, PHESGO, trastuzumab, tucatinib
format	article
author	Salkeni MA Rizvi W Hein K Higa GM
author_facet	Salkeni MA Rizvi W Hein K Higa GM
author_sort	Salkeni MA
title	Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
title_short	Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
title_full	Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
title_fullStr	Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
title_full_unstemmed	Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
title_sort	neu perspectives, therapies, and challenges for metastatic her2-positive breast cancer
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/46bae7ee4c0f4a189823d454f63a5b4d
work_keys_str_mv	AT salkenima neuperspectivestherapiesandchallengesformetastaticher2positivebreastcancer AT rizviw neuperspectivestherapiesandchallengesformetastaticher2positivebreastcancer AT heink neuperspectivestherapiesandchallengesformetastaticher2positivebreastcancer AT higagm neuperspectivestherapiesandchallengesformetastaticher2positivebreastcancer
_version_	1718379758022033408

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer

Ejemplares similares